title: Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
abstract: BACKGROUND
  Management of patients with differentiated thyroid carcinoma with negative diagnostic radioiodide scanning and increased serum thyroglobulin (Tg) concentrations is a widely debated problem. High-dose iodine-131 treatment of patients who have a negative (131)I diagnostic whole-body scan (WBS) is advocated. However, the therapeutic benefit of this "blind" treatment is not clear.
  
  
  OBJECTIVE
  To investigate the course of serum Tg during thyroid hormone suppression therapy (Tg-on) and clinical outcome in patients with negative diagnostic (131)I scanning and increased serum Tg concentrations during thyroid hormone withdrawal (Tg-off), after treatment with high-dose (131)I.
  
  
  METHODS
  Retrospective single-center study.
  
  
  METHODS
  Fifty-six patients were treated with a blind therapeutic dose of 150 mCi (131)I. Median follow-up from this treatment until the end of observation was 4.2 Years (range 0.5-13.5 Years).
  
  
  RESULTS
  The post-treatment WBS revealed (131)I uptake in 28 patients, but none in the remaining 28 patients. In this study the Tg-on values did not change after treatment in either the positive or the negative post-treatment WBS group. During follow-up, 18 of the 28 patients with a positive post-treatment WBS achieved complete remission, compared with 10 of the 28 patients with a negative post-treatment WBS. Nine patients in the negative group died, but no patients died in the positive post-treatment group (P=0.001).
  
  
  CONCLUSIONS
  High-dose iodine treatment in diagnostically negative patients who have a negative post-treatment scan seems to confer no additional value for tumor reduction and survival. In patients with a positive post-treatment scan, high-dose iodine treatment can be used as a diagnostic tool to identify tumor location, and a therapeutic effect may be present in individual cases.
authors.affiliation: Department of Endocrinology, University Hospital Groningen, University of Groningen, The Netherlands.
authors.forename: K M
authors.initials: KM
authors.lastname: van Tol
authors.forename: P L
authors.initials: PL
authors.lastname: Jager
authors.forename: E G E
authors.initials: EG
authors.lastname: de Vries
authors.forename: D A
authors.initials: DA
authors.lastname: Piers
authors.forename: H M
authors.initials: HM
authors.lastname: Boezen
authors.forename: W J
authors.initials: WJ
authors.lastname: Sluiter
authors.forename: R P F
authors.initials: RP
authors.lastname: Dullaart
authors.forename: T P
authors.initials: TP
authors.lastname: Links
mesh_terms: D018249:Adenoma, Oxyphilic / Q000097:blood / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002291:Carcinoma, Papillary / Q000097:blood* / Q000000981:diagnostic imaging* / Q000401:mortality / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D015996:Survival Rate; D013954:Thyroglobulin / Q000097:blood*; D013964:Thyroid Neoplasms / Q000097:blood* / Q000000981:diagnostic imaging* / Q000401:mortality / Q000601:surgery; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use; D016896:Treatment Outcome; D014915:Whole-Body Counting
chemical_list: D007457:Iodine Radioisotopes; D013972:Thyrotropin; D013954:Thyroglobulin; D013974:Thyroxine